Search for content, post, videos

BerGenBio appoints Chief Medical Officer

chief medical officer

BerGenBio has announced the appointment of Cristina Oliva as Chief Medical Officer (CMO).

Cristina Oliva joins the senior leadership team heading up clinical development of BerGenBio’s selective AXL inhibitor programs.

“I’m delighted to welcome Cristina as our new Chief Medical Officer. Cristina’s leadership experience within oncology drug development across big pharma, biotech and CRO environments will be instrumental in executing BerGenBio’s development strategy for our AXL inhibitor programs, including our most advanced program bemcentinib, currently in phase II trials,” says Martin Olin, Chief Executive Officer of BerGenBio.

Cristina Oliva

Cristina Oliva is a Board-certified oncologist and brings over 20 years of senior clinical development experience across large pharmaceutical, biotechnology and Clinical Research Organizations (CROs). Most recently she was Vice President, Oncology and Head of Oncology Centre of Excellence at IQVIA Ltd, where she led the development of decentralized trials and established and led the IQVIA Oncology Global Scientific Advisory Board. Prior to her role at IQVIA, she held senior positions leading oncology development programs for Nordic Nanovector, Takeda Pharmaceuticals, GlaxoSmithKline and Eli Lilly.

”BerGenBio is on the frontier of developing novel, highly selective AXL inhibitors for the treatment of severe diseases such as oncology and respiratory infections. I’m very excited to join BerGenBio at this critical phase and look forward to working with the senior leadership team to help further advance its AXL inhibitor programs,” says Cristina Oliva.

Photo: iStock